JEFFREY BROWN, PSY D
Social Work in Arlington, MA
License number
Massachusetts MA7415
Category
Social Work
Type
Clinical
Address
Address
691 Mass Ave, Arlington, MA 02476
Phone
(781) 641-1633
Personal information
See more information about JEFFREY BROWN at radaris.comName
Address
Phone
47 Chapel Rd, Savoy, MA 01256
49 Shattuck St, Greenfield, MA 01301
4 Garrison Ln #B, Southborough, MA 01772
4 Haywood Farm, Lynnfield, MA 01940
4 Lamplighter Ln, Walpole, MA 02081
Professional information
See more information about JEFFREY BROWN at trustoria.com
Jeffrey Brown, Arlington MA
Jeffrey Brown, Arlington MA
Specialties:
Psychologist
Address:
691 Massachusetts Ave, Arlington, MA 02476
Jeffrey Brown, Arlington MA
Jeffrey Brown, Arlington MA
Specialties:
Clinical Psychology
Address:
691 Massachusetts Ave, Arlington 02476
(781) 641-1633 (Phone)
(781) 641-1633 (Phone)
Languages:
English
Compositions And Methods For The Identification, Assessment, Prevention And Therapy Of Human Cancers
Compositions And Methods For The Identification, Assessment, Prevention And Therapy Of Human Cancers
US Patent:
7338758, Mar 4, 2008
Filed:
Feb 8, 2002
Appl. No.:
10/071510
Inventors:
Edwin Clark - Ashland MA, US
Tallessyn Grenfell-Lee - Cambridge MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Jeffrey L. Brown - Arlington MA, US
Tallessyn Grenfell-Lee - Cambridge MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Jeffrey L. Brown - Arlington MA, US
Assignee:
Mayo Foundation for Medical Education And Research. - Rochester MN
Board of Regents, The University of Texas System. - Austin TX
Millennium Pharmaceuticals, Inc. - Cambridge MA
Board of Regents, The University of Texas System. - Austin TX
Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C12Q 1/68
US Classification:
435 6, 536 231
Abstract:
The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers. ” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers. ” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
Compositions And Methods For The Identification, Assessment, Prevention, And Therapy Of Human Cancers
Compositions And Methods For The Identification, Assessment, Prevention, And Therapy Of Human Cancers
US Patent:
2002008, Jun 27, 2002
Filed:
Mar 22, 2001
Appl. No.:
09/816292
Inventors:
James Lillie - Natick MA, US
Jeffrey Brown - Arlington MA, US
Andrew Bolt - Cambridge MA, US
Christophe Huffel - Brussels, BE
Jeffrey Brown - Arlington MA, US
Andrew Bolt - Cambridge MA, US
Christophe Huffel - Brussels, BE
International Classification:
C12Q001/68, C12Q001/00, G01N033/574
US Classification:
435/006000, 435/004000, 435/007230
Abstract:
The present invention is directed to the identification of markers that can be used to determine whether cancer cells are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.
Novel Compositions And Methods For The Identification, Assessment, Prevention And Therapy Of Human Cancers
Novel Compositions And Methods For The Identification, Assessment, Prevention And Therapy Of Human Cancers
US Patent:
2012014, Jun 7, 2012
Filed:
Nov 4, 2011
Appl. No.:
13/289230
Inventors:
Edwin Clark - Pennington NJ, US
Tallessyn Grenfell-Lee - Cambridge MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester NY, US
Jeffrey L. Brown - Arlington MA, US
Gordon B. Mills - Houston TX, US
Tallessyn Grenfell-Lee - Cambridge MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester NY, US
Jeffrey L. Brown - Arlington MA, US
Gordon B. Mills - Houston TX, US
Assignee:
Millennium Pharmaceuticals, Inc. - Cambridge MA
Mayo Foundation for Medical Education and Research - Rochester MN
Board of Regents, The University of Texas System - Austin TX
Mayo Foundation for Medical Education and Research - Rochester MN
Board of Regents, The University of Texas System - Austin TX
International Classification:
C40B 30/04, A61K 33/24, A61P 35/00, A61K 31/337
US Classification:
424649, 506 9, 514449
Abstract:
The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
Novel Genes, Compositions And Methods For The Identification, Assessment, Prevention, And Therapy Of Human Cancers
Novel Genes, Compositions And Methods For The Identification, Assessment, Prevention, And Therapy Of Human Cancers
US Patent:
2002011, Aug 15, 2002
Filed:
Apr 13, 2001
Appl. No.:
09/834975
Inventors:
James Lillie - Natick MA, US
Jeffrey Brown - Arlington MA, US
Andrew Bolt - Cambridge MA, US
Christophe Huffel - Brussels, BE
Jeffrey Brown - Arlington MA, US
Andrew Bolt - Cambridge MA, US
Christophe Huffel - Brussels, BE
International Classification:
C12Q001/68, G01N033/574, C07H021/04, C12N009/00, C07K016/40, C07K016/30, C12N005/06
US Classification:
435/006000, 435/007230, 435/183000, 530/388260, 435/325000, 435/320100, 536/023200
Abstract:
The present invention is directed to the identification of markers that can be used to determine whether cancer cells are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.
Compositions And Methods For The Identification, Assessment, Prevention And Therapy Of Human Cancers
Compositions And Methods For The Identification, Assessment, Prevention And Therapy Of Human Cancers
US Patent:
8080368, Dec 20, 2011
Filed:
Nov 30, 2010
Appl. No.:
12/956500
Inventors:
Edwin Clark - Pennington NJ, US
Tallessyn Grenfell-Lee - Cambridge MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester NY, US
Jeffrey L. Brown - Arlington MA, US
Gordon B. Mills - Houston TX, US
Tallessyn Grenfell-Lee - Cambridge MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester NY, US
Jeffrey L. Brown - Arlington MA, US
Gordon B. Mills - Houston TX, US
Assignee:
Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C12Q 1/68, G01N 33/53
US Classification:
435 4, 435 6, 435 71, 530300, 530350, 536 235
Abstract:
The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers. ” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers. ” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
Compositions And Methods For The Identification, Assessment, Prevention And Therapy Of Human Cancers
Compositions And Methods For The Identification, Assessment, Prevention And Therapy Of Human Cancers
US Patent:
7871775, Jan 18, 2011
Filed:
Dec 17, 2007
Appl. No.:
12/002783
Inventors:
Edwin Clark - Ashland MA, US
Tallessyn Grenfell-Lee - Cambridge MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Jeffrey L. Brown - Arlington MA, US
Gordon B. Mills - Houston TX, US
Tallessyn Grenfell-Lee - Cambridge MA, US
Karen Lu - Houston TX, US
Lynn Hartmann - Rochester MN, US
Jeffrey L. Brown - Arlington MA, US
Gordon B. Mills - Houston TX, US
Assignee:
Millennium Pharmaceuticals, Inc - Cambridge MA
Mayo Foundation for Medical Edication and Research - Rochester MN
Board of Regents, The University of Texas System - Austin TX
Mayo Foundation for Medical Edication and Research - Rochester MN
Board of Regents, The University of Texas System - Austin TX
International Classification:
C12Q 1/68
US Classification:
435 6, 536 231
Abstract:
The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers. ” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers. ” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
Novel Compositions And Methods For The Identification, Assessment, Prevention, And Therapy Of Human Cancers
Novel Compositions And Methods For The Identification, Assessment, Prevention, And Therapy Of Human Cancers
US Patent:
2007019, Aug 16, 2007
Filed:
Dec 6, 2006
Appl. No.:
11/634620
Inventors:
Natalia Iartchouk - Wayland MA, US
Mark Ayers - Pennington NJ, US
Jeffrey Brown - Arlington MA, US
Robert Bast - Houston TX, US
Karen Lu - Houston TX, US
Gordon Mills - Houston TX, US
Mark Ayers - Pennington NJ, US
Jeffrey Brown - Arlington MA, US
Robert Bast - Houston TX, US
Karen Lu - Houston TX, US
Gordon Mills - Houston TX, US
Assignee:
MILLENNIUM PHARMACEUTICALS, INC. - Cambridge MA
Board of Regents, The University of Texas System - Austin TX
Board of Regents, The University of Texas System - Austin TX
International Classification:
C12Q 1/68, G01N 33/574, C12N 5/06, C07K 16/30
US Classification:
435006000, 435007230, 435338000, 530388800
Abstract:
The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.
Compositions And Methods For The Identification, Assessment, Prevention, And Therapy Of Human Cancers
Compositions And Methods For The Identification, Assessment, Prevention, And Therapy Of Human Cancers
US Patent:
7195868, Mar 27, 2007
Filed:
Apr 18, 2002
Appl. No.:
10/125159
Inventors:
Natalia Iartchouk - Belmont MA, US
Mark D. Ayers - Ayer MA, US
Jeffrey L. Brown - Arlington MA, US
Mark D. Ayers - Ayer MA, US
Jeffrey L. Brown - Arlington MA, US
Assignee:
Millennium Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C12Q 1/68
US Classification:
435 6, 536 231
Abstract:
The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers. ” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers. ” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.